Alvotech was founded in 2013 by the Chairman and CEO of Alvogen, Robert Wessman. Shortly after its creation, Alvotech announced its strategy to invest in the development and manufacturing of a portfolio of biosimilar monoclonal antibodies, followed by the ground breaking of its biomanufacturing facility in Reykjavik Iceland.
Since then, Alvotech’s investment commitment has increased to more than $500 million for the development of a pipeline of six monoclonal antibodies. Alvotech has established itself in the industry as a key player in the biosimilar space, with global partnerships in place, integrated development and a manufacturing platform in operation, as well as a solid pipeline in development and dedicated growing team of experts embracing our culture.
Meet us at .
Please tell us a little about yourself.